Opus Genetics (acquired in 2024)) Overview
- Year Founded
-
2021
- Status
-
Acquired/Merged
- Employees
-
13
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$25.8M
- Investors
-
1
Opus Genetics (acquired in 2024)) General Information
Description
Provider of a gene therapy intended to treat rare retinal degenerative diseases. The company offers adeno-associated virus-based gene therapies and helps in tackling manufacturing obstacles standing in the way of treatments, enabling businesses to provide access to treatments for blinding conditions efficiently.
Contact Information
(Operating Subsidiary)
Corporate Office
- 8 Davis Drive
- Durham, NC 27709
- United States
Corporate Office
- 8 Davis Drive
- Durham, NC 27709
- United States
Opus Genetics (acquired in 2024)) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 22-Oct-2024 | $25.8M | Completed | Generating Revenue | ||
| 3. Early Stage VC (Series A) | 27-Jun-2023 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 20-Aug-2021 | $19M | $19M | Completed | Clinical Trials - Phase 1 | |
| 1. University Spin-Out | 01-Jan-2021 | Completed | Startup |
Opus Genetics (acquired in 2024)) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
Opus Genetics (acquired in 2024)) Patents
Opus Genetics (acquired in 2024)) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026122826-A1 | Methods and compositions for improving visual performance under mesopic light conditions using phentolamine | Pending | 05-Dec-2024 | ||
| WO-2026055508-A1 | Methods and compositions for treating and preventing the progression of intermediate age-related macular degeneration and related conditions | Pending | 06-Sep-2024 | ||
| WO-2025194083-A1 | Compositions comprising an apx3330 hemicalcium salt monohydrate and therapeutic uses thereof | Pending | 14-Mar-2024 | ||
| EP-4559900-A1 | Phentolamine mesylate and therapeutic uses thereof | Pending | 21-Nov-2023 | ||
| US-20250162995-A1 | Phentolamine mesylate and therapeutic uses thereof | Pending | 21-Nov-2023 | A61K31/417 |
Opus Genetics (acquired in 2024)) Signals
Opus Genetics (acquired in 2024)) Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bios Partners | Venture Capital | Minority | ||
| Manning Family Foundation | Limited Partner | Minority | ||
| Michigan Capital Network | Venture Capital | Minority | ||
| Retinal Degeneration Fund | Not-For-Profit Venture Capital | Minority |
Opus Genetics (acquired in 2024)) FAQs
-
When was Opus Genetics (acquired in 2024)) founded?
Opus Genetics (acquired in 2024)) was founded in 2021.
-
Where is Opus Genetics (acquired in 2024)) headquartered?
Opus Genetics (acquired in 2024)) is headquartered in Durham, NC.
-
What is the size of Opus Genetics (acquired in 2024))?
Opus Genetics (acquired in 2024)) has 13 total employees.
-
What industry is Opus Genetics (acquired in 2024)) in?
Opus Genetics (acquired in 2024))’s primary industry is Drug Discovery.
-
Is Opus Genetics (acquired in 2024)) a private or public company?
Opus Genetics (acquired in 2024)) is a Private company.
-
What is the current valuation of Opus Genetics (acquired in 2024))?
The current valuation of Opus Genetics (acquired in 2024)) is .
-
What is Opus Genetics (acquired in 2024))’s current revenue?
The current revenue for Opus Genetics (acquired in 2024)) is .
-
How much funding has Opus Genetics (acquired in 2024)) raised over time?
Opus Genetics (acquired in 2024)) has raised $23.5M.
-
Who are Opus Genetics (acquired in 2024))’s investors?
Bios Partners, Manning Family Foundation, Michigan Capital Network, and Retinal Degeneration Fund have invested in Opus Genetics (acquired in 2024)).
-
When was Opus Genetics (acquired in 2024)) acquired?
Opus Genetics (acquired in 2024)) was acquired on 22-Oct-2024.
-
Who acquired Opus Genetics (acquired in 2024))?
Opus Genetics (acquired in 2024)) was acquired by Opus Genetics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process